Company Neumora Therapeutics, Inc.

Equities

NMRA

US6409791000

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 01:08:02 2024-05-16 pm EDT			5-day change	1st Jan Change
9.62 ^USD	-0.52%		-1.23%	-43.40%

May. 14	Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression	MT
May. 14	Neumora Therapeutics, Inc. Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression	CI

Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Companyâs therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Its other candidates include NMRA-266, NMRA-511, and NMRA-NMDA. NMRA-266 is a positive allosteric modulator program of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia. NMRA-266 is designed to be selective for the M4 receptor subtype of the muscarinic receptor family. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-NMDA is an NMDA positive allosteric modulator program that the Company is developing for the treatment of schizophrenia.

Number of employees: 120

Managers	Title	Age	Since
Carol Suh FOU	Founder	33	19-10-31
Henry Gosebruch CEO	Chief Executive Officer	51	23-07-17
Paul Berns FOU	Founder	57	19-10-31
Joshua Pinto DFI	Director of Finance/CFO	38	21-05-31
Raj Manchanda CTO	Chief Tech/Sci/R&D Officer	58	23-06-30
Nicholas Brandon CTO	Chief Tech/Sci/R&D Officer	50	20-03-31
Robert Lenz CTO	Chief Tech/Sci/R&D Officer	-	23-10-09
Maryjo Chamberlain-Tharp PRN	Corporate Officer/Principal	48	21-07-31
Amy Sullivan HRO	Human Resources Officer	-	20-12-31
Lori Houle PRN	Corporate Officer/Principal	57	21-03-31

Members of the board	Title	Age	Since
Paul Berns FOU	Founder	57	19-10-31
May Kin Ho BRD	Director/Board Member	71	21-03-31
Kristina Burow BRD	Director/Board Member	50	19-12-31
Matthew Fust BRD	Director/Board Member	59	20-11-30
Henry Gosebruch CEO	Chief Executive Officer	51	23-07-17
Alaa Halawa BRD	Director/Board Member	42	21-08-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	159,523,997	114,732,490 ( 71.92 %)	0	71.92 %

Name	Equities	%	Valuation
AMGEN INC. 22.26 %	35,368,653	22.26 %	320 M $
ARCH Venture Partners LLC 20.10 %	31,932,138	20.10 %	289 M $
Biomatics Capital Management CO LLC 4.948 %	7,861,859	4.948 %	71 M $
Paul Berns 4.813 %	7,646,916	4.813 %	69 M $
SoftBank Capital Partners LLC 4.813 %	7,646,916	4.813 %	69 M $
Impresa Management LLC 3.540 %	5,624,353	3.540 %	51 M $
MIC Capital Management UK LLP 2.807 %	4,460,700	2.807 %	40 M $
T. Rowe Price Investment Management, Inc. 2.256 %	3,584,004	2.256 %	32 M $
ICONIQ Capital LLC 2.139 %	3,398,628	2.139 %	31 M $
Wellcome Trust Ltd. (Direct Investments) 2.083 %	3,309,123	2.083 %	30 M $

Neumora Therapeutics, Inc.

490 Arsenal Way Suite 200

02472, Watertown

http://www.neumoratx.com

address Neumora Therapeutics, Inc.(NMRA)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

9.67 USD

Average target price

24.51 USD

Spread / Average Target

+153.45%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
NEUMORA THERAPEUTICS, INC.	-43.40%	1.54B
MODERNA, INC.	+33.05%	49.46B
IQVIA HOLDINGS INC.	+1.99%	42.58B
LONZA GROUP AG	+49.11%	42.49B
CELLTRION, INC.	-4.22%	29.09B
ICON PUBLIC LIMITED COMPANY	+12.08%	26.61B
ALNYLAM PHARMACEUTICALS, INC.	-22.51%	18.64B
BIO-TECHNE CORPORATION	+8.41%	13.16B
MEDPACE HOLDINGS, INC.	+30.32%	12.55B
UNITED THERAPEUTICS CORPORATION	+24.03%	12.1B

Other Biotechnology & Medical Research